`

Tagged: DT-DEC01

Trial for Duchenne muscular dystrophy cell therapy.

January 27th, 2022 | DT-DEC01

Duchenne Muscular Dystrophy is the most common fatal genetic disorder to affect children around the world. The first patient, a six year old boy, received, in November 2021, an infusion of DT-DEC01, a novel cell therapy containing Dystrophin Expressing Chimeric Cells (DEC),  in Phase I pilot clinical study for the treatment of Duchenne muscular dystrophy (DMD). […]

Pin It on Pinterest